Your browser doesn't support javascript.
No evidence for basigin/CD147 as a direct SARS-CoV-2 spike binding receptor.
Shilts, Jarrod; Crozier, Thomas W M; Greenwood, Edward J D; Lehner, Paul J; Wright, Gavin J.
  • Shilts J; Cell Surface Signalling Laboratory, Wellcome Sanger Institute, Cambridge, UK. js44@sanger.ac.uk.
  • Crozier TWM; Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, UK.
  • Greenwood EJD; Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, UK.
  • Lehner PJ; Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, UK.
  • Wright GJ; Cell Surface Signalling Laboratory, Wellcome Sanger Institute, Cambridge, UK. gw2@sanger.ac.uk.
Sci Rep ; 11(1): 413, 2021 01 11.
Article in English | MEDLINE | ID: covidwho-1019887
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
The spike protein of SARS-CoV-2 is known to enable viral invasion into human cells through direct binding to host receptors including ACE2. An alternate entry receptor for the virus was recently proposed to be basigin/CD147. These early studies have already prompted a clinical trial and multiple published hypotheses speculating on the role of this host receptor in viral infection and pathogenesis. Here, we report that we are unable to find evidence supporting the role of basigin as a putative spike binding receptor. Recombinant forms of the SARS-CoV-2 spike do not interact with basigin expressed on the surface of human cells, and by using specialized assays tailored to detect receptor interactions as weak or weaker than the proposed basigin-spike binding, we report no evidence for a direct interaction between the viral spike protein to either of the two common isoforms of basigin. Finally, removing basigin from the surface of human lung epithelial cells by CRISPR/Cas9 results in no change in their susceptibility to SARS-CoV-2 infection. Given the pressing need for clarity on which viral targets may lead to promising therapeutics, we present these findings to allow more informed decisions about the translational relevance of this putative mechanism in the race to understand and treat COVID-19.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Receptors, Virus / Basigin / Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 Type of study: Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Sci Rep Year: 2021 Document Type: Article Affiliation country: S41598-020-80464-1

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Receptors, Virus / Basigin / Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 Type of study: Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Sci Rep Year: 2021 Document Type: Article Affiliation country: S41598-020-80464-1